{
    "clinical_study": {
        "@rank": "154786", 
        "arm_group": [
            {
                "arm_group_label": "DuoTrav\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks."
            }, 
            {
                "arm_group_label": "Beta-blocker monotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Subject's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with\n      travoprost 0.004% / timolol 0.5% (DuoTrav\u00ae) compared to beta-blocker monotherapy in patients\n      with open-angle glaucoma or ocular hypertension."
        }, 
        "brief_title": "Global DuoTrav\u00ae Study", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Open Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a clinical diagnosis of either open angle glaucoma or ocular hypertension.\n\n          -  Currently on beta-blocker monotherapy (for >30 days) and would benefit, in the\n             opinion of the investigator, from further lOP reduction.\n\n          -  Have a mean baseline lOP of >18 mmHg and <32 mmHg in at least one eye.\n\n          -  Must be able to understand and sign an Informed Consent form.\n\n          -  Other protocol-specified inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Severe central visual field loss in either eye within the last year.\n\n          -  Chronic, recurrent or severe inflammatory eye disease (e.g., sclerotic, uveitis, or\n             herpes keratitis).\n\n          -  Ocular trauma or surgery within the past 6 months.\n\n          -  Ocular infection or ocular inflammation within the past 3 months.\n\n          -  Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to\n             20/80 Snellen, 0.60 logMAR or 0.25 decimal).\n\n          -  Any abnormality preventing reliable measurement of IOP.\n\n          -  Other ocular pathology (including severe dry eye) that may, in the opinion of the\n             investigator, preclude the administration of study medication.\n\n          -  Condition that requires the use of any additional topical or systemic ocular\n             hypotensive medication during the study.\n\n          -  Hypersensitivity to prostaglandin analogues or any component of the study medications\n             in the opinion of the investigator.\n\n          -  Asthma, history of asthma, or severe chronic obstructive pulmonary disease.\n\n          -  Condition that does not allow the patient to discontinue all glucocorticoids\n             administered by any route safely.\n\n          -  Therapy with another investigational agent within 30 days prior to Visit 1.\n\n          -  Any other condition including severe illness which would make the patient, in the\n             opinion of the investigator, unsuitable for the study.\n\n          -  Women of childbearing potential if pregnant, test positive for pregnancy at Screening\n             visit, breastfeeding, or not in agreement to use adequate birth control methods to\n             prevent pregnancy throughout the study.\n\n          -  Other protocol-specified exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "156", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003391", 
            "org_study_id": "M-13-038"
        }, 
        "intervention": [
            {
                "arm_group_label": "Beta-blocker monotherapy", 
                "description": "Per subject's current prescribed therapy", 
                "intervention_name": "Beta-blocker monotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DuoTrav\u00ae", 
                    "Beta-blocker monotherapy"
                ], 
                "intervention_name": "Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DUOTRAV\u2122 BAK", 
                    "DUOTRAV\u00ae PQ"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adrenergic beta-Antagonists", 
                "Timolol", 
                "Travoprost"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Open Angle Glaucoma", 
            "Ocular Hypertension", 
            "DuoTrav\u00ae", 
            "Intraocular Pressure"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav\u00ae in Patients Previously Uncontrolled on a Beta-blocker", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Danyel Carr, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Human Research Bioethics Committee", 
                "Australia: Human Research Ethics Committee", 
                "Mexico: Ethics Committee", 
                "Korea: Institutional Review Board", 
                "Russia: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "IOP (fluid pressure inside the eye) will be assessed using Goldmann applanation tonometry and is measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).", 
            "measure": "Intraocular pressure (IOP) at 8AM", 
            "safety_issue": "No", 
            "time_frame": "Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003391"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "IOP (fluid pressure inside the eye) will be assessed using Goldmann applanation tonometry and is measured in mmHg. A negative change indicates an improvement.", 
                "measure": "Mean change from baseline in IOP (8AM) at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 0), Week 4"
            }, 
            {
                "description": "IOP (fluid pressure inside the eye) will be assessed using Goldmann applanation tonometry and is measured in mmHg. A negative change indicates an improvement.", 
                "measure": "Percentage change from baseline in IOP (8AM) at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 0), Week 4"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}